Cargando…
mHealth Monitoring of Treatment of Cutaneous Leishmaniasis Patients: A Community-Based Implementation Study
Cutaneous leishmaniasis (CL) remains a global health problem. Compelled by the protracted healing process, initial and final outcomes of treatment are determined at 90 and 180 days, respectively, after initiation of treatment. Loss to follow-up during these intervals is substantial. Consequently, th...
Autores principales: | Cossio, Alexandra, Bautista-Gomez, Martha Milena, Alexander, Neal, del Castillo, Alejandra María, Castro, María del Mar, Castaño-Grajales, Patricia Yaneth, Gutiérrez-Poloche, Yeison Hawer, Zuluaga, Laura Sofía, Vargas-Bernal, Leonardo, Navarro, Andrés, Saravia, Nancy Gore |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Tropical Medicine and Hygiene
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551068/ https://www.ncbi.nlm.nih.gov/pubmed/37640290 http://dx.doi.org/10.4269/ajtmh.22-0805 |
Ejemplares similares
-
Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis
por: Castro, María del Mar, et al.
Publicado: (2017) -
Randomized trial evaluating an mHealth intervention for the early community-based detection and follow-up of cutaneous leishmaniasis in rural Colombia
por: Castillo, Mabel, et al.
Publicado: (2023) -
Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis
por: Berger, Brandon A., et al.
Publicado: (2017) -
Pentoxifylline in the Treatment of Cutaneous Leishmaniasis: A Randomized Clinical Trial in Colombia
por: Castro, Maria del Mar, et al.
Publicado: (2022) -
Immuno-pharmacokinetics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia)
por: Gómez, María Adelaida, et al.
Publicado: (2020)